Foundation Medicine Inc (FMI)

20.74
NASDAQ : Health Care
Prev Close 20.76
Day Low/High 20.31 / 21.37
52 Wk Low/High 13.34 / 25.98
Avg Volume 231.30K
Exchange NASDAQ
Shares Outstanding 34.93M
Market Cap 725.09M
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

Foundation Medicine, Inc. (NASDAQ: FMI) today announced that the U.

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Investors eyeing a purchase of Foundation Medicine Inc shares, but tentative about paying the going market price of $23.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $15 strike, which has a bid at the time of this writing of 75 cents.

Foundation Medicine Announces Timing For Second Quarter 2016 Financial Results And Conference Call

Foundation Medicine Announces Timing For Second Quarter 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's second quarter ended June 30, 2016, will be released on Tuesday, August 2, 2016.

Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders

Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders

Stocks with insider trader activity include EGLT, FMI and ICLD

Foundation Medicine (FMI) Is Strong On High Volume Today

Foundation Medicine (FMI) Is Strong On High Volume Today

Trade-Ideas LLC identified Foundation Medicine (FMI) as a strong on high relative volume candidate

Foundation Medicine Announces Release Of Molecular Information From FoundationCORE™ To The National Cancer Institute In Support Of The National Cancer Moonshot And Precision Medicine Initiatives

Foundation Medicine Announces Release Of Molecular Information From FoundationCORE™ To The National Cancer Institute In Support Of The National Cancer Moonshot And Precision Medicine Initiatives

Foundation Medicine, Inc. (NASDAQ:FMI) announced today that the company will release approximately 18,000 genomic profiles of adult cancers from its FoundationCORE ™ knowledgebase to the National Cancer...

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.

Insider Trading Alert - FMI, GNTX And CNBKA Traded By Insiders

Insider Trading Alert - FMI, GNTX And CNBKA Traded By Insiders

Stocks with insider trader activity include FMI, GNTX and CNBKA

New Data From Foundation Medicine And Collaborators Supports Use Of Comprehensive Genomic Profiling To Inform Therapeutic Choices In Advanced Breast Cancer

New Data From Foundation Medicine And Collaborators Supports Use Of Comprehensive Genomic Profiling To Inform Therapeutic Choices In Advanced Breast Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) today presented new data in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 that underscore the critical importance of integrating...

Data From A Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles In Acute Myeloid Leukemia

Data From A Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles In Acute Myeloid Leukemia

Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data informed by comprehensive genomic profiling (CGP) using FoundationOne® Heme demonstrating the diverse and distinct genomic landscape of acute...

Foundation Medicine Presents New Data At ASCO 2016 Demonstrating That FoundationOne® May Help Predict Response To Cancer Immunotherapy Across A Variety Of Advanced Cancers

Foundation Medicine Presents New Data At ASCO 2016 Demonstrating That FoundationOne® May Help Predict Response To Cancer Immunotherapy Across A Variety Of Advanced Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) and it collaborators presented data showing that higher tumor mutational burden, as estimated by comprehensive genomic profiling with FoundationOne ®, successfully...

FoundationOne® Identifies Patients With Advanced Lung Cancer Likely To Respond Or Develop Resistance To Certain RET Inhibitor Therapies

FoundationOne® Identifies Patients With Advanced Lung Cancer Likely To Respond Or Develop Resistance To Certain RET Inhibitor Therapies

Foundation Medicine, Inc. (NASDAQ:FMI) today announced new critical genomics data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 demonstrating the clinical significance of comprehensive genomic...

Foundation Medicine And AstraZeneca Enter Strategic Collaboration For Lynparza Companion Diagnostic Assay

Foundation Medicine And AstraZeneca Enter Strategic Collaboration For Lynparza Companion Diagnostic Assay

Foundation Medicine, Inc. (NASDAQ:FMI) and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global...

Foundation Medicine To Present At The Goldman Sachs Annual Healthcare Conference

Foundation Medicine To Present At The Goldman Sachs Annual Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the Goldman Sachs Annual Healthcare Conference on Wednesday, June 8, 2016, at 2:00 p.

Foundation Medicine Announces Presentations At ASCO

Foundation Medicine Announces Presentations At ASCO

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical...

Foundation Medicine Receives Patent Covering Fundamental Methods In Comprehensive Genomic Analysis In Cancer

Foundation Medicine Receives Patent Covering Fundamental Methods In Comprehensive Genomic Analysis In Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.

Notable Thursday Option Activity: FMI, SHLD, GPRO

Notable Thursday Option Activity: FMI, SHLD, GPRO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Foundation Medicine Inc , where a total volume of 1,423 contracts has been traded thus far today, a contract volume which is representative of approximately 142,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 67.2% of FMI's average daily trading volume over the past month, of 211,810 shares.

Foundation Medicine Announces 2016 First Quarter Results And Recent Highlights

Foundation Medicine Announces 2016 First Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2016.

Foundation Medicine Announces Commercial Launch Of Liquid Biopsy Assay, FoundationACT™

Foundation Medicine Announces Commercial Launch Of Liquid Biopsy Assay, FoundationACT™

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of FoundationACT (Assay for Circulating Tumor DNA), an analytically validated and accurate blood-based circulating tumor DNA (ctDNA) assay that provides...

Foundation Medicine And AstraZeneca Collaborate To Develop Companion Diagnostic Assays In Oncology

Foundation Medicine And AstraZeneca Collaborate To Develop Companion Diagnostic Assays In Oncology

Foundation Medicine, Inc. (NASDAQ:FMI) today announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to...

Commit To Buy Foundation Medicine At $12.50, Earn 19.4% Annualized Using Options

Commit To Buy Foundation Medicine At $12.50, Earn 19.4% Annualized Using Options

Investors eyeing a purchase of Foundation Medicine Inc shares, but tentative about paying the going market price of $16.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $12.50 strike, which has a bid at the time of this writing of $1.35.

Foundation Medicine To Present At Upcoming Investor Conferences

Foundation Medicine To Present At Upcoming Investor Conferences

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Bank of America Merrill Lynch 2016...

Foundation Medicine's Molecular Information Supports Discovery Of Precision Therapeutics For Pediatric Cancers

Foundation Medicine's Molecular Information Supports Discovery Of Precision Therapeutics For Pediatric Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) today presented new data from more than 1,200 pediatric tumors across 51 cancer subtypes that were analyzed using the company's comprehensive genomic profiling assays,...

GlaxoSmithKline, PetMed Among 4 Stocks Poised to Go Higher

GlaxoSmithKline, PetMed Among 4 Stocks Poised to Go Higher

Shares of GlaxoSmithKline are up a pleasant 5% in 2016, and it currently sports a healthy 6.5% dividend yield.

Foundation Medicine Announces Timing For First Quarter 2016 Financial Results And Conference Call

Foundation Medicine Announces Timing For First Quarter 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2016, will be released on Tuesday, May 3, 2016.

Insider Trading Alert - SKT, FMI And DXCM Traded By Insiders

Insider Trading Alert - SKT, FMI And DXCM Traded By Insiders

Stocks with insider trader activity include SKT, FMI and DXCM

New Data With FoundationOne® Supports Clinical Utility And Improved Outcomes From Molecularly Matching Non-Small Cell Lung Cancer Patients To Targeted Therapy

New Data With FoundationOne® Supports Clinical Utility And Improved Outcomes From Molecularly Matching Non-Small Cell Lung Cancer Patients To Targeted Therapy

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the publication of two manuscripts that underscore the importance of integrating comprehensive genomic profiling with FoundationOne® into the management of...

Foundation Medicine And Memorial Sloan Kettering Publish Validation Data For FoundationOne® Heme In The Journal Blood

Foundation Medicine And Memorial Sloan Kettering Publish Validation Data For FoundationOne® Heme In The Journal Blood

Foundation Medicine, Inc. (NASDAQ:FMI) and Memorial Sloan Kettering Cancer Center (MSK) today announced the publication of new, seminal data validating FoundationOne® Heme - the fully informative comprehensive...